JP2021521856A5 - - Google Patents
Info
- Publication number
- JP2021521856A5 JP2021521856A5 JP2020560400A JP2020560400A JP2021521856A5 JP 2021521856 A5 JP2021521856 A5 JP 2021521856A5 JP 2020560400 A JP2020560400 A JP 2020560400A JP 2020560400 A JP2020560400 A JP 2020560400A JP 2021521856 A5 JP2021521856 A5 JP 2021521856A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- foxp3
- cells
- promoter
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024182581A JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2026060213A JP2026108825A (ja) | 2018-04-27 | 2026-04-01 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663545P | 2018-04-27 | 2018-04-27 | |
| US62/663,545 | 2018-04-27 | ||
| PCT/US2019/029082 WO2019210042A1 (en) | 2018-04-27 | 2019-04-25 | Expression of foxp3 in edited cd34+ cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024182581A Division JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521856A JP2021521856A (ja) | 2021-08-30 |
| JP2021521856A5 true JP2021521856A5 (enExample) | 2022-11-25 |
| JP7575950B2 JP7575950B2 (ja) | 2024-10-31 |
Family
ID=68294731
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2026060213A Pending JP2026108825A (ja) | 2018-04-27 | 2026-04-01 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024182581A Active JP7844582B2 (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2026060213A Pending JP2026108825A (ja) | 2018-04-27 | 2026-04-01 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11713459B2 (enExample) |
| EP (1) | EP3784690A4 (enExample) |
| JP (3) | JP7575950B2 (enExample) |
| CN (1) | CN112218882A (enExample) |
| AU (2) | AU2019261438B2 (enExample) |
| CA (1) | CA3091688A1 (enExample) |
| IL (1) | IL277039A (enExample) |
| SG (1) | SG11202007878UA (enExample) |
| WO (1) | WO2019210042A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042179A1 (en) | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| JP7575949B2 (ja) | 2018-04-27 | 2024-10-31 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現 |
| SG11202007878UA (en) * | 2018-04-27 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Expression of foxp3 in edited cd34+ cells |
| AU2020209687A1 (en) * | 2019-01-18 | 2021-07-29 | Osaka University | Composition for use in treating dystrophic epidermolysis bullosa |
| JP2022533713A (ja) | 2019-05-21 | 2022-07-25 | サンガモ セラピューティクス， インコーポレイテッド | 調節性ｔ細胞における制御された導入遺伝子発現 |
| EP3980035A4 (en) | 2019-06-07 | 2023-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY |
| AU2020304057A1 (en) * | 2019-06-27 | 2022-01-27 | Benaroya Research Institute At Virginia Mason | Artificial antigen-specific immunoregulatory t (airt) cells |
| CA3160113A1 (en) | 2019-11-08 | 2021-05-14 | Sangamo Therapeutics, Inc. | Generation of engineered regulatory t cells |
| WO2021144692A1 (en) * | 2020-01-14 | 2021-07-22 | Crispr Therapeutics Ag | Methods for increased efficiency of homology-directed repair |
| EP4103591A4 (en) | 2020-02-13 | 2024-09-04 | The Board of Trustees of the Leland Stanford Junior University | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients |
| TW202233830A (zh) * | 2020-10-27 | 2022-09-01 | 美商Ｐａｃｔ製藥公司 | 使用下一代工程化t細胞療法治療癌症之組合物及方法 |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100996016B1 (ko) | 2000-09-20 | 2010-11-22 | 밀리포어 코포레이션 | 폴리뉴클레오티드 |
| US7507542B2 (en) | 2001-05-08 | 2009-03-24 | Ucb Sa | Method for regulating immune function using the FOXP3 protein |
| GB0614536D0 (en) | 2006-07-21 | 2006-08-30 | Metcalfe Susan M | Methods of controlling cellular response to LIF |
| WO2008066784A2 (en) * | 2006-11-27 | 2008-06-05 | Ludwig Institute For Cancer Research | Expression of foxp3 by cancer cells |
| PT2126054T (pt) | 2007-01-31 | 2016-10-12 | Yeda Res & Dev | Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US20110123502A1 (en) | 2007-02-21 | 2011-05-26 | Barry Simon C | Method for obtaining treg-cells |
| US8158596B2 (en) | 2007-05-11 | 2012-04-17 | The Regents Of The University Of Michigan | Materials and methods for FOXP3 tumor suppression |
| US8846308B2 (en) | 2007-06-08 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Method for identifying immune response modulators |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| EP2279030A2 (en) | 2008-03-03 | 2011-02-02 | Fabio Grassi | Method of modulating t cell-dependent immune responses |
| US8772028B2 (en) * | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
| WO2012018930A1 (en) | 2010-08-03 | 2012-02-09 | University Of Miami | Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy |
| WO2014180943A1 (en) | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
| CA2912375C (en) | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| EP3119897A1 (en) | 2014-03-21 | 2017-01-25 | Cellectis | Engineering mammalian genome using dna-guided argonaute interference systems (dais) |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| AU2016206870B2 (en) | 2015-01-12 | 2022-02-17 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| US20190388469A1 (en) | 2015-01-30 | 2019-12-26 | The Regents Of The University Of California | Protein delivery in primary hematopoietic cells |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| EP3448995A1 (en) | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
| EP3497221A4 (en) | 2016-08-10 | 2020-02-05 | Duke University | COMPOSITIONS, SYSTEMS AND METHODS FOR PROGRAMMING IMMUNE CELL FUNCTION BY TARGETED GENE REGULATION |
| EP3500696A4 (en) | 2016-08-16 | 2020-04-08 | Bluebird Bio, Inc. | VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| EP3532075A4 (en) * | 2016-10-27 | 2020-07-08 | Intima Bioscience, Inc. | VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS |
| CA3042179A1 (en) | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| CA3045667A1 (en) | 2016-12-13 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| CN109790518A (zh) | 2017-05-08 | 2019-05-21 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| WO2019040655A1 (en) | 2017-08-22 | 2019-02-28 | The Regents Of The University Of California | LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES |
| JP7575949B2 (ja) | 2018-04-27 | 2024-10-31 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現 |
| SG11202007878UA (en) * | 2018-04-27 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Expression of foxp3 in edited cd34+ cells |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
-
2019
- 2019-04-25 SG SG11202007878UA patent/SG11202007878UA/en unknown
- 2019-04-25 CN CN201980028370.7A patent/CN112218882A/zh active Pending
- 2019-04-25 JP JP2020560400A patent/JP7575950B2/ja active Active
- 2019-04-25 AU AU2019261438A patent/AU2019261438B2/en active Active
- 2019-04-25 CA CA3091688A patent/CA3091688A1/en active Pending
- 2019-04-25 US US16/981,223 patent/US11713459B2/en active Active
- 2019-04-25 EP EP19793428.4A patent/EP3784690A4/en active Pending
- 2019-04-25 WO PCT/US2019/029082 patent/WO2019210042A1/en not_active Ceased
-
2020
- 2020-08-31 IL IL277039A patent/IL277039A/en unknown
-
2023
- 2023-06-16 US US18/336,276 patent/US20240117352A1/en active Pending
-
2024
- 2024-10-18 JP JP2024182581A patent/JP7844582B2/ja active Active
- 2024-11-22 AU AU2024266824A patent/AU2024266824A1/en active Pending
-
2026
- 2026-04-01 JP JP2026060213A patent/JP2026108825A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521849A5 (enExample) | ||
| AU2021277627B2 (en) | Anti-CD70-chimeric antigen receptors | |
| Bailey et al. | Gene editing for immune cell therapies | |
| Khan et al. | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors | |
| KR102859521B1 (ko) | 지속 치료를 위한 나노입자 조성물 | |
| JP7844582B2 (ja) | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 | |
| CA3042179A1 (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene | |
| JP6998211B2 (ja) | 腫瘍抗原ｎｙ－ｅｓｏ－１のｍｈｃ ｉおよびｍｈｃ ｉｉ拘束性エピトープに対する、癌の併用ｔ細胞受容体遺伝子療法 | |
| McNamee et al. | Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohnˈs-like murine ileitis | |
| JP2025013884A5 (enExample) | ||
| US20190322983A1 (en) | Engineered treg cells | |
| JP2025013879A5 (enExample) | ||
| JP2020529834A5 (enExample) | ||
| JP2020528744A5 (enExample) | ||
| JP2015078191A5 (enExample) | ||
| JP2019514373A5 (enExample) | ||
| Bucciol et al. | Recent advances in primary immunodeficiency: from molecular diagnosis to treatment | |
| EP4057807A1 (en) | Genetically modified non-human animal with human or chimeric genes | |
| JP2024505075A5 (enExample) | ||
| AU2018336522A1 (en) | A gRNA targeting HPK1 and a method for editing HPK1 gene | |
| JP2018509909A5 (enExample) | ||
| JP7669345B2 (ja) | Ｔ細胞受容体及びその使用方法 | |
| Lantow et al. | The granulocyte colony stimulating factor pathway regulates autoantibody production in a murine induced model of systemic lupus erythematosus | |
| IL315188A (en) | Methods and compositions comprising fusion proteins for improved immunotherapies | |
| JP2025515095A (ja) | Ｈｌａ－ｅおよびｈｌａ－ｇ導入遺伝子を用いて操作された細胞 |